- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 233/88 - Nitrogen atoms, e.g. allantoin
Patent holdings for IPC class C07D 233/88
Total number of patents in this class: 352
10-year publication summary
|
18
|
22
|
27
|
20
|
23
|
19
|
20
|
29
|
15
|
11
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Pfizer Inc. | 3367 |
14 |
| SpringWorks Therapeutics, Inc. | 135 |
14 |
| AstraZeneca AB | 2898 |
9 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2172 |
9 |
| Novartis AG | 10727 |
8 |
| Epigen Biosciences, Inc. | 13 |
7 |
| Buck Institute for Research on Aging | 126 |
6 |
| Nippon Soda Co., Ltd. | 895 |
6 |
| Merck Sharp & Dohme LLC | 3748 |
6 |
| Bristol-myers Squibb Company | 4872 |
5 |
| BASF SE | 20967 |
5 |
| Dana-Farber Cancer Institute, Inc. | 2574 |
5 |
| North Carolina State University | 1566 |
5 |
| The Regents of the University of California | 20015 |
4 |
| Gilead Sciences, Inc. | 2041 |
4 |
| Katholieke Universiteit Leuven | 1198 |
4 |
| Romark Laboratories L.C. | 52 |
4 |
| Merck Patent GmbH | 5814 |
3 |
| Astex Therapeutics Limited | 242 |
3 |
| BIAL - Portela & CA, S.A. | 224 |
3 |
| Other owners | 228 |